Health Tech Capitol | ‘Landmark year’: Exact Sciences touts 64 percent rise in Cologuard test use in 2018
16605
post-template-default,single,single-post,postid-16605,single-format-standard,tribe-no-js,tribe-bar-is-disabled,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-9.3,wpb-js-composer js-comp-ver-4.12,vc_responsive

‘Landmark year’: Exact Sciences touts 64 percent rise in Cologuard test use in 2018

22 Feb ‘Landmark year’: Exact Sciences touts 64 percent rise in Cologuard test use in 2018

Posted at 09:01h in Uncategorized by
0 Likes

Calling it “a landmark year,” Exact Sciences Corp. CEO and chairman Kevin Conroy said 934,000 people used the company’s Cologuard home test kit for colorectal cancer in 2018, an increase of 64 percent from the year before.

That brought in $454.5 million in revenue for the Madison diagnostic test company, up 71 percent from Exact’s $266 million in revenue in 2017.

Exact’s net loss also rose, hitting $175.1 million, or $1.43 a share, for 2018 compared with a net loss of $114.4 million, or 99 cents a share, for 2017. Chief financial officer Jeff Elliott said the cost of new employees hired for sales and customer care contributed to that, as well as research on new cancer test products.

Read more at the Wisconsin State Journal

No Comments

Sorry, the comment form is closed at this time.